Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14436530 | 1.00 | ATM (0.39) | ATMDPP4DPP8DPP9PIK3CD | |
| SCHEMBL7892261 | 1.00 | ATM (0.39) | ATMDPP4DPP8DPP9PIK3CD | |
| SCHEMBL13963737 | 1.00 | ATM (0.39) | ATMDPP4DPP8DPP9PIK3CD | |
| SCHEMBL24311898 | 0.85 | ATM (0.37) | ATM | |
| SCHEMBL20329583 | 0.85 | GAA (0.32) | — | |
| SCHEMBL19483347 | 0.85 | GAA (0.32) | — | |
| SCHEMBL7744767 | 0.85 | GAA (0.32) | — | |
| SCHEMBL15905731 | 0.82 | ATM (0.53) | ATMDPP4DPP8DPP9PIK3CD | |
| SCHEMBL24004323 | 0.82 | ATM (0.53) | ATMDPP4DPP8DPP9PIK3CD | |
| SCHEMBL5021550 | 0.82 | ATM (0.53) | ATMDPP4DPP8DPP9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220080051-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | ATM 2614/4885DPP4 1304/4885DPP8 980/4885 |
| US-20220080051-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | ATM 2614/4885DPP4 1304/4885DPP8 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.